Skip to content
PeptideTech
Cart

Home / Research library / Retatrutide

Peptides

Retatrutide: molecular data, studies & sources

Retatrutide is a peptide studied as a triple GIP, GLP-1 and glucagon receptor agonist. A randomized phase 2 obesity trial enrolled 338 adults and followed treatment for 48 weeks. The study reported weight reductions and adverse events, including gastrointestinal events and changes in heart rate. Its results apply to the investigational formulation and selected trial population; they do not establish the identity, quality or safety of research-vendor material.

Overview sources: PMID 37366315 · PMID 35985340

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C221H342N46O68
Molecular weight (MW)
4731 g/mol
PubChem compound ID
171390338
Record title
Triple G

This structure is linked through the IUPHAR depositor record (SID 507750402), whose compound title is Triple G. It represents the referenced molecule, not a tested supplier batch.

Source: PubChem CID 171390338 · retrieved 2026-09-21 · Identity cross-reference

PubChem 2D molecular structure for Retatrutide, CID 171390338
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
20-[[(1S)-4-[2-[2-[2-[[(5S)-5-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-6-[[(2S)-1-[[(2S)-5-amino-1-[[1-[[(2S)-1-[[(2S)-1-[[(3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
InChIKey
MLOLQJNKXBNWFW-SAGGEDDASA-N
SMILES
CC[C@H](C)C(C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@](C)(CC(C)C)NC(=O)C([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC9=CC=C(C=C9)O)N
Machine-readable PubChem source

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

  1. Human study · PubMed trial index

    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

    Jastreboff AM, Kaplan LM, Frías JP et al. · The New England journal of medicine · 2023

    Randomized, double-blind, placebo-controlled phase 2 study in 338 adults with obesity. Reports 48-week weight outcomes and adverse events; vendor research products were not evaluated.

    PMID 37366315 · DOI: 10.1056/NEJMoa2301972

  2. Mixed laboratory and early human research

    LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

    Coskun T, Urva S, Roell WC et al. · Cell metabolism · 2022

    Discovery and translational report combining receptor experiments, mouse data and an early human dose-escalation study. These stages answer different questions.

    PMID 35985340 · DOI: 10.1016/j.cmet.2022.07.013

  3. Human study · PubMed trial index

    Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

    Sanyal AJ, Kaplan LM, Frias JP et al. · Nature medicine · 2024

    PMID 38858523 · DOI: 10.1038/s41591-024-03018-2

  4. Human study · PubMed trial index

    Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.

    Bajaj HS, Welch M, Shah P et al. · Lancet (London, England) · 2026

    PMID 42250575 · DOI: 10.1016/S0140-6736(26)00967-0

  5. Human study · PubMed trial index

    Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

    Rosenstock J, Frias J, Jastreboff AM et al. · Lancet (London, England) · 2023

    PMID 37385280 · DOI: 10.1016/S0140-6736(23)01053-X

  6. Human study · PubMed trial index

    Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.

    Coskun T, Wu Q, Schloot NC et al. · The lancet. Diabetes & endocrinology · 2025

    PMID 40609566 · DOI: 10.1016/S2213-8587(25)00092-0

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

  1. Review · secondary evidence

    Retatrutide-A Game Changer in Obesity Pharmacotherapy.

    Katsi V, Koutsopoulos G, Fragoulis C et al. · Biomolecules · 2025

    PMID 40563436 · DOI: 10.3390/biom15060796

  2. Research publication · design requires review

    Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.

    Giblin K, Kaplan LM, Somers VK et al. · Diabetes, obesity & metabolism · 2026

    PMID 41090431 · DOI: 10.1111/dom.70209

Retatrutide supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Compare all Retatrutide sizes, forms and supplier prices →

SupplierRecorded packagesExample source listing
Blank PeptidesUSD10mg Vial · 20mg Vial · 30mg Vial · 15mg Vial4 recorded offers10mg Vial · $105.00Checked Sep 21, 2026Supplier listing
American PeptidesUSD10mg Vial · 20mg Vial · 30mg Vial3 recorded offers10mg Vial · $105.00Checked Sep 21, 2026Supplier listing
Modified AminosUSD30mg Vial · 10mg Vial · 20mg Vial3 recorded offers30mg Vial · $99.99Checked Sep 16, 2026Supplier listing
Amino ClubUSD10mg Vial · 20mg Vial · 30mg Vial3 recorded offers10mg Vial · $69.99Checked Sep 16, 2026Supplier listing
US Peptide LabsUSD10mg Vial · 20mg Vial · 40mg Vial · 40mg Nasal spray · 20mg Nasal spray · 20mg Oral spray · 40mg Oral spray7 recorded offers10mg Vial · $100.00Checked Sep 16, 2026Supplier listing
Direct PeptidesUSD10mg Vial · 15mg Vial · 30mg Vial3 recorded offers10mg Vial · $79.00Checked Sep 16, 2026Supplier listing
Particle PeptidesEUR10mg Vial1 recorded offers10mg Vial · €149.99Checked Sep 16, 2026Supplier listing
Nuvion PeptidesCAD10mg Vial · 30mg Vial2 recorded offers10mg Vial · CA$99.99Checked Sep 21, 2026Supplier listing
PhaseOneAUD5mg Vial · 10mg Vial · 15mg Vial · 20mg Vial · 30mg Vial · 60mg Vial6 recorded offers5mg Vial · A$76.99Checked Sep 21, 2026Supplier listing
AllMyPeptidesGBP10mg Vial · 20mg Vial · 30mg Vial · 40mg Vial · 60mg Vial5 recorded offers10mg Vial · £42.99Checked Sep 17, 2026Supplier listing

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles